Clinical Trials Logo

Clinical Trial Summary

The primary features of schizophrenia and schizoaffective disorder are characterized by positive (inability to think clearly and distinguish reality from fantasy) and negative symptoms (reduction or absence of normal behavior or emotions). Other symptoms include reduced ability to recall and learn information, difficulty in problem solving or maintaining productive employment. Asenapine is an investigational drug that may help to correct the above characteristics of schizophrenia by altering the inbalance of brain hormones such as dopamine and serotonin. This is a 12-month trial that will test the efficacy and safety of asenapine using an active comparator (olanzapine) in the treatment of patients with schizophrenia. Patients who complete the 12-month trial will have the option of continuing on drug until the treatment code for the 12-month trial is unblinded.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00212784
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date September 4, 2003
Completion date March 15, 2006

See also
  Status Clinical Trial Phase
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Active, not recruiting NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Recruiting NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Recruiting NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A
Completed NCT02304432 - Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine Early Phase 1
Completed NCT01222793 - Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia N/A
Enrolling by invitation NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Recruiting NCT02868879 - Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia
Completed NCT02212041 - Electronic Cigarettes in Smokers With Mental Illness N/A
Suspended NCT01878513 - Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis N/A
Recruiting NCT03163706 - Evaluation of Stroop Effect in Patients With Schizophrenia N/A
Enrolling by invitation NCT00001921 - Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings
Not yet recruiting NCT02879604 - Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia N/A
Recruiting NCT02823041 - Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode N/A
Recruiting NCT02906553 - The Role of Nitric Oxide in Cognition in Schizophrenia N/A
Recruiting NCT02832401 - The Impact of Caffeine on Cognition in Schizophrenia N/A
Recruiting NCT02796144 - MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Phase 4
Recruiting NCT02864576 - Cognitive Remediation Plus Aerobic Exercise in Schizophrenia Treatment N/A
Recruiting NCT02782442 - "Cognitive Training Delivered Remotely to Individuals With Psychosis N/A